|
1
|
Kruse JP and Gu W: Modes of p53
regulation. Cell. 137:609–622. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P,
Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al: A global map of
p53 transcription-factor binding sites in the human genome. Cell.
124:207–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View
Article : Google Scholar
|
|
6
|
Tchelebi L, Ashamalla H and Graves PR:
Mutant p53 and the response to chemotherapy and radiation. Subcell
Biochem. 85:133–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheok CF, Verma CS, Baselga J and Lane DP:
Translating p53 into the clinic. Nat Rev Clin Oncol. 8:25–37. 2011.
View Article : Google Scholar
|
|
8
|
Lane DP, Cheok CF and Lain S: p53-based
cancer therapy. Cold Spring Harb Perspect Biol. 2:a0012222010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tallen G and Riabowol K: Keep-ING balance:
Tumor suppression by epigenetic regulation. FEBS Lett.
588:2728–2742. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiseki M, Nagashima M, Pedeux RM,
Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y,
Appella E, Yokota J, et al: p29ING4 and p28ING5 bind to p53 and
p300, and enhance p53 activity. Cancer Res. 63:2373–2378.
2003.PubMed/NCBI
|
|
11
|
Zhang X, Xu LS, Wang ZQ, Wang KS, Li N,
Cheng ZH, Huang SZ, Wei DZ and Han ZG: ING4 induces G2/M cell cycle
arrest and enhances the chemosensitivity to DNA-damage agents in
HepG2 cells. FEBS Lett. 570:7–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Unoki M, Shen JC, Zheng ZM and Harris CC:
Novel splice variants of ING4 and their possible roles in the
regulation of cell growth and motility. J Biol Chem.
281:34677–34686. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie Y, Zhang H, Sheng W, Xiang J, Ye Z and
Yang J: Adeno-virus-mediated ING4 expression suppresses lung
carcinoma cell growth via induction of cell cycle alteration and
apoptosis and inhibition of tumor invasion and angiogenesis. Cancer
Lett. 271:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai L, Li X, Zheng S, Wang Y, Wang Y, Li
H, Yang J and Sun J: Inhibitor of growth 4 is involved in
melanomagenesis and induces growth suppression and apoptosis in
melanoma cell line M14. Melanoma Res. 19:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gong A, Ye S, Xiong E, Guo W, Zhang Y,
Peng W, Shao G, Jin J, Zhang Z, Yang J, et al: Autophagy
contributes to ING4-induced glioma cell death. Exp Cell Res.
319:1714–1723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie Y, Sheng W, Miao J, Xiang J and Yang
J: Enhanced antitumor activity by combining an adenovirus harboring
ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Ther.
18:176–188. 2011. View Article : Google Scholar :
|
|
17
|
Zhao Y, Su C, Zhai H, Tian Y, Sheng W,
Miao J and Yang J: Synergistic antitumor effect of
adenovirus-mediated hING4 gene therapy and (125)I radiation therapy
on pancreatic cancer. Cancer Lett. 316:211–218. 2012. View Article : Google Scholar
|
|
18
|
Ling C, Xie Y, Zhao D, Zhu Y, Xiang J and
Yang J: Enhanced radiosensitivity of non-small-cell lung cancer
(NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther.
19:697–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim S, Chin K, Gray JW and Bishop JM: A
screen for genes that suppress loss of contact inhibition:
Identification of ING4 as a candidate tumor suppressor gene in
human cancer. Proc Natl Acad Sci USA. 101:16251–16256. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen JC, Unoki M, Ythier D, Duperray A,
Varticovski L, Kumamoto K, Pedeux R and Harris CC: Inhibitor of
growth 4 suppresses cell spreading and cell migration by
interacting with a novel binding partner, liprin alpha1. Cancer
Res. 67:2552–2558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Martinka M and Li G: Role of ING4 in
human melanoma cell migration, invasion and patient survival.
Carcinogenesis. 29:1373–1379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garkavtsev I, Kozin SV, Chernova O, Xu L,
Winkler F, Brown E, Barnett GH and Jain RK: The candidate tumour
suppressor protein ING4 regulates brain tumour growth and
angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nozell S, Laver T, Moseley D, Nowoslawski
L, De Vos M, Atkinson GP, Harrison K, Nabors LB and Benveniste EN:
The ING4 tumor suppressor attenuates NF-kappaB activity at the
promoters of target genes. Mol Cell Biol. 28:6632–6645. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ozer A, Wu LC and Bruick RK: The candidate
tumor suppressor ING4 represses activation of the hypoxia inducible
factor (HIF). Proc Natl Acad Sci USA. 102:7481–7486. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Colla S, Tagliaferri S, Morandi F, Lunghi
P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L,
Ravanetti L, et al: The new tumor-suppressor gene inhibitor of
growth family member 4 (ING4) regulates the production of
proangiogenic molecules by myeloma cells and suppresses
hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: Involvement
in myeloma-induced angiogenesis. Blood. 110:4464–4475. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hou Y, Zhang Z, Xu Q, Wang H, Xu Y and
Chen K: Inhibitor of growth 4 induces NFκB/p65 ubiquitin-dependent
degradation. Oncogene. 33:1997–2003. 2014. View Article : Google Scholar
|
|
27
|
Lu M, Pan C, Zhang L, Ding C, Chen F, Wang
Q, Wang K and Zhang X: ING4 inhibits the translation of
proto-oncogene MYC by interacting with AUF1. FEBS Lett.
587:1597–1604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brenner MK, Gottschalk S, Leen AM and Vera
JF: Is cancer gene therapy an empty suit? Lancet Oncol.
14:e447–e456. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wilson DR: Viral-mediated gene transfer
for cancer treatment. Curr Pharm Biotechnol. 3:151–164. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang Y, Zhao W, Chen Y, Zhao Y and Gu W:
Acetylation is indispensable for p53 activation. Cell. 133:612–626.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xie Y, Lv H, Sheng W, Miao J, Xiang J and
Yang J: Synergistic tumor suppression by adenovirus-mediated
inhibitor of growth 4 and interleukin-24 gene cotransfer in
hepatocarcinoma cells. Cancer Biother Radiopharm. 26:681–695. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Y, Ye T, Sun D, Maynard J and
Deisseroth A: Conditionally replication-competent adenoviral
vectors with enhanced infectivity for use in gene therapy of
melanoma. Hum Gene Ther. 15:637–647. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang W, Qin SK, Chen BA and Chen HY:
Experimental study on antitumor effect of arsenic trioxide in
combination with cisplatin or doxorubicin on hepatocellular
carcinoma. World J Gastroenterol. 7:702–705. 2001.
|
|
36
|
Brooks CL and Gu W: Ubiquitination,
phosphorylation and acetylation: The molecular basis for p53
regulation. Curr Opin Cell Biol. 15:164–171. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang X, Wang KS, Wang ZQ, Xu LS, Wang QW,
Chen F, Wei DZ and Han ZG: Nuclear localization signal of ING4
plays a key role in its binding to p53. Biochem Biophys Res Commun.
331:1032–1038. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Massagué J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hung T, Binda O, Champagne KS, Kuo AJ,
Johnson K, Chang HY, Simon MD, Kutateladze TG and Gozani O: ING4
mediates crosstalk between histone H3 K4 trimethylation and H3
acetylation to attenuate cellular transformation. Mol Cell.
33:248–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Welti J, Loges S, Dimmeler S and Carmeliet
P: Recent molecular discoveries in angiogenesis and antiangiogenic
therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shang B, Cao Z and Zhou Q: Progress in
tumor vascular normalization for anticancer therapy: Challenges and
perspectives. Front Med. 6:67–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ravi R, Mookerjee B, Bhujwalla ZM, Sutter
CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL and Bedi A:
Regulation of tumor angiogenesis by p53-induced degradation of
hypoxia-inducible factor 1alpha. Genes Dev. 14:34–44.
2000.PubMed/NCBI
|
|
45
|
Yamakuchi M, Lotterman CD, Bao C, Hruban
RH, Karim B, Mendell JT, Huso D and Lowenstein CJ: P53-induced
micro-RNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad
Sci USA. 107:6334–6339. 2010. View Article : Google Scholar
|
|
46
|
Teodoro JG, Parker AE, Zhu X and Green MR:
p53-mediated inhibition of angiogenesis through up-regulation of a
collagen prolyl hydroxylase. Science. 313:968–971. 2006. View Article : Google Scholar : PubMed/NCBI
|
